Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: STRATEGY IN MOTION: THE CURRENT AND FUTURE LIFECYCLE APPROACH TO DECISION MAKING ON HEALTH TECHNOLOGIES

Presentation
François Meyer, Advisor to the President, International Affairs, French National Authority for Health (HAS), Saint-Denis La Plaine, France
Presentation
Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA), London, UK
Presentation
Jerome Boehm, Team Leader, Health Technology Assessment, Directorate-General for Health and Food Safety, European Commission, Brussels, Belgium
Presentation
Finn Børlum Kristensen, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
Presentation
Mirella Marlow, Programme Director, Devices and Diagnostics Systems, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

 

SECOND PLENARY SESSION: OUTCOMES RESEARCH: ARE WE READY TO PUT THEORY INTO PRACTICE?

Presentation
Lorenzo G Mantovani, Associate Professor of Public Health, Center for Public Health Research (CESP), University of Milano-Bicocca, Monza, Italy
Presentation
Walter Ricciardi, President, Italian National Institute of Health (ISS) and Past-President, European Public Health Association (EUPHA), Rome, Italy
Presentation
Sergio Pecorelli, Chairman of the Board, Italian Medicines Agency (AIFA) and Professor, Department of Obstetrics and Gynecology, & Chancellor, University of Brescia, Brescia, Italy
Presentation
Brian O'Rourke, President and Chief Executive Officer, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada
Presentation
Mario Strazzabosco, Deputy Director, Yale Liver Center & Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine and Director, Department of Surgical and Interdisciplinary Medicine, University of Milano-Bicocca, Monza, Italy

 

THIRD PLENARY SESSION: RECOMMENDATIONS FROM THE ISPOR MULTI-CRITERIA DECISION ANALYSIS EMERGING GOOD PRACTICE TASK FORCE AND REMAINING CONTROVERSIES

Presentation
Daniel Malone, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
Presentation
Maarten J. IJzerman, Professor of Clinical Epidemiology & HTA & Vice Dean, Health & Biomedical Technology, Faculty of Science & Technology, University of Twente, Enschede, The Netherlands
Presentation
Kevin Marsh, Senior Research Scientist & EU Director of Modelling and Simulation, Evidera, London, UK
Presentation
A. Brett Hauber, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
Presentation
Mónica Duarte Oliveira, Associate Professor, Department of Engineering and Management, Instituto Superior Técnico, University of Lisbon, Lisbon, Portugal
Presentation
Nancy Devlin, Director of Research, Office of Health Economics, London, UK
Praveen Thokala, Research Fellow, University of Sheffield, Sheffield, UK

 

ISSUE PANEL PRESENTATIONS

IP1 : WHAT IS THE ROLE OF ECONOMIC EVALUATION IN PRICING AND REIMBURSEMENT OF MEDICINES?: A COMPARISON BETWEEN ENGLAND, GERMANY, AND FRANCE

Presentation
Meindert Boysen, Programme Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK
Presentation
Jean-Luc Harousseau, President, French National Authority for Health (HAS), Saint-Denis La Plaine, France
Presentation
Andreas Gerber-Grote, Head of Health Economics, Institute for Quality and Efficiency in Healthcare (IQWiG), Cologne, Germany

 

IP2 : POSSIBLE INCREASED SYNERGY BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REGULATORY AGENCIES: OPPORTUNITY OR CHALLENGE FOR MEDICAL DEVICES?

Presentation
Pascale Brasseur, Chair, HTA Working Group, Eucomed, Brussels, Belgium
Presentation
François Meyer, Advisor to the President, International Affairs, French National Authority for Health (HAS), Paris, France
Presentation
Les Levin, Founding Chief Scientific Officer, MaRS EXCITE, Toronto, ON, Canada

 

IP3 : SPEED OR LESS UNCERTAINTY? TRADE-OFFS IN ADAPTIVE PATHWAY IMPLEMENTATION AND POTENTIAL PRICING AND REIMBURSEMENT RESPONSES

Presentation
Martin Buxton, Emeritus Professor, Health Economics Research Group (HERG), Brunel University, Uxbridge, UK
Presentation
Yvonne-Beatrice Boehler, Professor for Pharmamanagement, Faculty of Applied Natural Sciences, Cologne University of Applied Sciences, Leverkusen, Germany
Presentation
Susanne Michel, European Practice Lead, Evidera, London, UK
Presentation
J Jaime Caro, Chief Scientist, Evidera, Lexington, MA, USA

 

IP4 : MANAGEMENT OF SPECIALTY DRUGS IN THE UNITED STATES AND EUROPE: ARE WE BALANCING INNOVATION AND AFFORDABILITY?

Presentation
James Robinson, Professor, Public Health, University of California, Berkeley, Berkeley, CA, USA
Presentation
Ansgar Hebborn, Head - Global HTA & Payment Policy, Global Pricing & Market Access, F. Hoffmann-La Roche AG, Basel, Switzerland

 

IP5 : BLOG IT, TWEET IT, LIKE IT, OR BIN IT? THE ROLE OF SOCIAL MEDIA DATA IN PATIENT-REPORTED OUTCOMES RESEARCH

Presentation
Diana Rofail, Global Head of Patient-Centered Outcomes Research, Neuroscience and Metabolism, Roche Products Limited, Welwyn Garden City, UK
Thomas G Willgoss, Project Lead, Clinical Outcomes Assessment, Abacus International, Manchester, UK
Louise Humphrey, Director, Abacus International, Manchester, UK
Raj Mahapatra, Chair, National Ankylosing Spondylitis Society, London, UK

 

IP6 : ASSESSMENT OF THE VALUE OF MEDICAL DEVICES: CAN WE SIMPLY APPLY PROCESSES ESTABLISHED FOR DRUGS OR DO WE NEED TO PURSUE SEPARATE PROCESSES FOR DEVICES?

Presentation
Alric Ruether, Head, Department of Health Care Quality, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

 

IP7 : ARE CURRENT ICER THRESHOLDS OUTDATED? DOES MCDA OFFER A MORE HOLISTIC APPROACH TO ASSESSING THE VALUE OF INNOVATIVE TECHNOLOGIES?

Presentation
Zeba M. Khan, Vice President, Celgene Corporation, Summit, NJ, USA
Andrew Briggs, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
John Proach, Executive Vice President, Pricing and Market Access, Market Access Solutions LLC, Raritan, NJ, USA
Maarten J. IJzerman, Professor of Clinical Epidemiology & HTA & Vice Dean, Health & Biomedical Technology, Faculty of Science & Technology, University of Twente, Enschede, The Netherlands

 

IP8 : THE COST OF NO EUROPE: ARE THERE COSTS AND CONSEQUENCES OF LOCALIZED OR CENTRALIZED ASSESSMENT OF RELATIVE EFFICACY?

Presentation
Carole Longson, Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK
Jacco Keja, Senior Principal, Real-World Evidence Solutions & HEOR, IMS Health, London, UK and Lecturer, RWES, IMS Health, Rotterdam, The Netherlands
Alastair Kent, Director, Genetic Alliance UK, London, UK
Andrea Rappagliosi, Vice President, Market Access, Health Policy and Medical Affairs, Sanofi Pasteur MSD, Lyon, France

 

IP10 : QUALITY-ADJUSTED LIFE YEARS (QALYS) – HELP OR HINDRANCE IN SUPPORTING HEALTH CARE DECISION MAKING?

Presentation
Mark J. Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Ariel Beresniak, Chief Executive Officer, Data Mining International, Geneva, Switzerland

 

IP11 : BUILDING LIGHT HTA APPROACH IN CENTRAL AND EASTERN EUROPEAN COUNTRIES BASED ON HTA RECOMMENDATIONS IN WESTERN EUROPEAN COUNTRIES: MORE HARM THAN GOOD?

Presentation
Katarzyna Kolasa, Market Access Director, Oy H. Lundbeck Ab, Turku, Finland
Presentation
Mirjana Huic, Assistant Director, Department for Development, Research and Health Technology Assessment, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
Presentation
Finn Børlum Kristensen, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
Presentation
Zoltán Kaló, Professor of Health Economics, Department of Health Policy and Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary

 

IP12 : WHAT ARE THE OPPORTUNITIES AND CHALLENGES IN DEVELOPING TRANSPARENCY OF CLINICAL (TRIAL) DATA?

Presentation
Richard Bergstrom, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium
Presentation
Beate Wieseler, Head of Drug Assessment, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Presentation
Noel Wathion, Chief Policy Adviser, European Medicines Agency (EMA), London, UK

 

IP13 : BEST AVAILABLE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT DECISION MAKING: EFFICACY OR EFFECTIVENESS?

Presentation
Robert B McQueen, Health Economist, Research in Real Life (RiRL), Cambridge, UK

 

IP14 : VALUING HEALTH: HAVE WE REALLY GOT IT RIGHT?

Presentation
Paul Kind, Professor, Centre for Health Economics, Management and Policy, HSE University, St Petersburg, Russia
Ben van Hout, Professor, School of Health and Related Research (ScHARR), The University of Sheffield, Sheffield, UK
Pauline McNulty, Vice President, Patient Reported Outcomes, JGS USA Janssen Global Services, Johnson & Johnson, Raritan, NJ, USA

 

IP15 : THE TRUTH, THE WHOLE TRUTH, AND NOTHING BUT THE TRUTH: SHOULD WE STICK TO PRAGMATIC INCREMENTALISM OR IS IT TIME TO TAKE COST-EFFECTIVENESS ANALYSES UP TO THE LEVEL OF DISEASE MODELLING?

Presentation
Michel van Agthoven, Head of Market Access, GILEAD Sciences, Amsterdam, The Netherlands
Saskia Knies, Policy Advisor Health Economics, National Health Care Institute (ZiN), Diemen, The Netherlands
Margreet Franken, Scientific Researcher, Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands
Carin Uyl-de Groot, Professor Health Technology Assessment, Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands

 

IP16 : OUTCOME-BASED AGREEMENTS: HIGHLY USEFUL BUT TOO DIFFICULT TO IMPLEMENT – IS THAT TRUE?

Presentation
Francois Lucas, Principal Consultant, Pope Woodhead & Associates Ltd, St. Ives, UK
Kathleen E. Hughes, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA
Swati Mehta, Associate Director, Pricing and Market Access, Bristol-Myers Squibb, Uxbridge, UK
Livio Garattini, Director, Centre of Health Economics, Marionegri Institute, Panica (BG), Italy

 

IP17 : JOINT ASSESSMENTS IN EUROPE: CAN WE DO IT AND HOW?

Presentation
Wim Goettsch, Advisor International Affairs, National Healthcare Institute (ZiN), Diemen, The Netherlands
Presentation
Luciana Ballini, Head of Regional Observatory for Innovation, Regional Agency for Health and Social Care – Emilia-Romagna, Bologna, Italy
Presentation
Zoe Garrett, Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

 

IP18 : TO SEEK OR NOT TO SEEK PARALLEL EUROPEAN MEDICINES AGENCY (EMA)/HEALTH TECHNOLOGY ASSESSMENT (HTA) SCIENTIFIC ADVICE? THAT IS THE QUESTION

Presentation
Ansgar Hebborn, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland
Trent McLaughlin, Vice President, Xcenda, Palm Harbor, FL, USA
Eldon Spackman, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
Thomas J Bramley, Senior Vice President, Xcenda, Palm Harbor, FL, USA

 

IP19 : HOW DO WE EVALUATE TECHNOLOGIES WHICH ARE NOT COST-EFFECTIVE AT A ZERO PRICE?

Presentation
Ron Akehurst, Strategic Director, BresMed Health Solutions Ltd, Sheffield, UK
Presentation
Ben van Hout, Scientific Director, Pharmerit International, York, UK
Presentation
Sarah Davis, Senior Lecturer in Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Presentation
Janet Robertson, Associate Director, Technology Appraisals, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

 

IP20 : PATIENT-REPORTED OUTCOMES: CAN THEIR USE IN OBSERVATIONAL (“REAL-WORLD”) RESEARCH BE CONSIDERED INTERVENTIONAL?

Presentation
Matthew Reaney, Senior Research Scientist, ERT, Peterborough, UK
Erin Tomaszewski, Clinical Outcomes Research Scientist, Quintiles, Durham, NC, USA
Olivier Chassany, Director, Patient-Centered Outcomes Research, Paris, France

 

WORKSHOP PRESENTATIONS

W1 : DEFINING AND VALUING INNOVATION IN ONCOLOGY

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Monique Martin, Vice President & General Manager HEOR Europe, MAPI, Uxbridge, UK
Alistair Mcguire, Professor of Health Economics, LSE Health, London School of Economics, London, UK
Elizabeth Jones, Project Leader, HEOR Europe, MAPI, Uxbridge, UK

 

W2 : THE PUB & THE P-SUB: A POTENTIAL FRAMEWORK DEVELOPED TO ASSESS THE NEED FOR AND DESIGN OF MANAGED ENTRY AGREEMENTS FOR NEW DRUGS

Presentation
Mark J. Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Alan Brennan, Professor of Health Economics and Decision Modelling, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Presentation
Johan L. Severens, Professor of Evaluation in Health Care, Institute of Health Policy and Management, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
Presentation
Sabine Grimm, PhD Candidate, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

 

W3 : ADJUSTING FOR TIME-DEPENDING CONFOUNDING AND CROSSOVER BIAS IN OBSERVATIONAL STUDIES AND CLINICAL TRIALS: PURPOSE, METHODS, AND ACCEPTANCE IN HTA

Presentation
Uwe Siebert, Professor, Department of Public Health & HTA/ONCTYROL, Area 4 HTA & Bioinformatics/Harvard T.H. Chan School of Public Health, Center for Health Decision Science, Department of Health Policy & Management, Harvard Medical School, Institute for Technology Assessment & Department of Radiology, Hall i.T., Austria
Lars Beckmann, Research Fellow, Institute for Quality and Efficiency in Healthcare (IQWIG), Cologne, Germany
Felicitas Kuehne, Senior Scientist, Public Health and Health Technology Assessment, UMIT, Hall i.T., Austria
Nicholas Latimer, Senior Research Fellow in Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

 

W4 : MAKING SENSE OF NOVEL APPROACHES FOR INDIRECT COMPARISON: SIMILARITIES AND DIFFERENCES OF SIMULATION AND MATCHING BASED APPROACHES

Presentation
K. Jack Ishak, Senior Research Leader, Evidera, Montreal, QC, Canada
Cristina Masseria, Director Outcomes & Evidence, Global Health & Value, Pfizer Inc., New York, NY, USA
Hemant Phatak, Group Director, Global Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA

 

W6 : ASSESSING MEDICATION ADHERENCE: PATIENT-REPORTED, CLINICAL, PHARMACOEPIDEMIOLOGIC, AND ECONOMIC APPROACHES

Presentation
Sarah Clifford, Director, ICON Commercialisation and Outcomes, ICON Clinical Research, LLC, San Francisco, CA, USA
RA Elliott, Lord Trent Professor of Medicines and Health, Social Research in Medicines and Health School of Pharmacy, University of Nottingham, Nottingham, UK
Lina Eliasson, Lead Outcomes Researcher, ICON PRO, Oxford, UK
Shelagh Szabo, Director & Head of Evidence Generation, Redwood Outcomes, Vancouver, BC, Canada

 

W7 : MARKET ACCESS 2020: WHAT ARE THE NEXT CHALLENGES?

Presentation
Mondher Toumi, Professor of Public Health, Department of Public Health, Aix-Marseille University, Marseille, France
Presentation
Jan Mueller-Berghaus, Paul-Ehrlich- Institute (PEI), Langen, Germany
Presentation
Meriem Bouslouk, Officer, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany

 

W8 : EVIDENCE SYNTHESIS BASED ON AGGREGATE AND INDIVIDUAL-LEVEL DATA: CONSIDERATIONS FOR USE IN HTA DECISION MAKING

Presentation
Keith R Abrams, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK
Presentation
Pedro Saramago Goncalves, Research Fellow, Centre of Health Economics, University of York, Heslington, York, UK
Presentation
Yumi Asukai, Director, R&D Value Evidence Analytics, GSK, Uxbridge, UK
Presentation
Timothy Reason, Senior Consultant, Real-World Evidence Solutions, IMS Health, London, UK

 

W9 : DEVELOPMENT OF EVIDENCE PACKAGES FOR REGULATORY AND REIMBURSEMENT SUBMISSIONS IN RARE DISEASES: REAL-WORLD EXAMPLES

Presentation
Vasudha Bal, Director, Patient Reported Outcomes, Worldwide Health Outcomes, Value & Access, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Nicola Bonner, Senior Research Manager, EDOA, Adelphi Values Ltd, Bollington, UK
Alexandra Bowden, Senior Manager, Ultragenyx Pharmaceutical Inc., Novato, CA, USA
Anne Kilburg, Principal Consultant, Wellmera AG, Basel, Switzerland

 

W10 : MOVING THE SCIENCE FORWARD: TACKLING KEY PSYCHOMETRIC AND METHODOLOGICAL ISSUES FACING THE FIELD OF CLINICAL OUTCOME ASSESSMENT

Presentation
Antoine Regnault, Research Director, HEOR & Strategic Market Access, Mapi, Lyon, France
Kathleen W. Wyrwich, Executive Director, Center of Excellence, Outcomes Research, Evidera, Bethesda, MD, USA
Stephen Joel Coons, Executive Director, PRO Consortium, Critical Path Institute, Tucson, AZ, USA
Tara Symonds, COA Strategy Lead & Partner, Clinical Outcomes Solutions Ltd., Folkestone, Kent, UK

 

W11 : TRANSLATING PHARMACOMETRICS TO PHARMACOECONOMICS

Presentation
Richard J. Willke, Vice President, Outcomes & Evidence Lead CV/Metabolic, Pain, Urology, Gender Health, Global Health & Value, Pfizer Inc., New York, NY, USA
Julia F Slejko, Assistant Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Scott Marshall, Senior Director, Pharmacometrics, Global Clinical Pharmacology, Pfizer, Inc, Sandwich, UK

 

W12 : OPTIMIZING PATIENT INVOLVEMENT IN PAYER HEALTH CARE DECISIONS TO ACCESS NEW THERAPIES

Presentation
Michael Barry, Clinical Director, National Centre for Pharmacoeconomics, Dublin, Ireland
Presentation
Nicola Bedlington, Director, European Patients' Forum, Brussels, Belgium
Presentation
Veronica Foote, Head of Patient Relations & External Communications, Novartis Oncology Europe, Surrey, UK

 

W13 : THE ROLE OF VALUE OF INFORMATION IN HTA: ARE WE MISSING AN OPPORTUNITY?

Presentation
Mark Strong, Clinical Senior Lecturer in Public Health, School of Health and Related Research, University of Sheffield, Sheffield, UK
Nicky J. Welton, Reader in Evidence Synthesis, School of Social and Community Medicine, University of Bristol, Bristol, UK
Anna Heath, PhD Student, Statistical Science, University College London, London, UK
Gianluca Baio, Reader in Statistics & Health Economics, Statistical Science, University College London, London, UK

 

W14 : ORPHAN DRUG EVIDENCE REQUIREMENTS FOR POSITIVE HTA RECOMMENDATIONS

Presentation
Mondher Toumi, Professor of Public Health, Department of Public Health, Aix-Marseille University, Marseille, France
Presentation
François Meyer, Advisor to the President, International Affairs, French National Authority for Health (HAS), Paris, France
Presentation
Josie Godfrey, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK
Presentation
Meriem Bouslouk, Officer, Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany

 

W16 : RETROSPECTIVE HEALTH OUTCOMES RESEARCH AND HEALTH-ECONOMIC EVALUATION BASED ON REAL-WORLD DATA ANALYSES IN EUROPE: DATA AVAILABILITY, STRENGTHS AND LIMITATIONS, AND DATABASE-SPECIFIC CONSIDERATIONS

Presentation
Thomas Wilke, Partner, Ingress-Health, Wismar, Germany
Presentation
Myrthe P. P. van Herk-Sukel, Manager, Research Department, Epidemiologist, PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands
Presentation
Wilhelmine Meeraus, Research Scientist, Medicines and Healthcare Products Regulatory Agency, The Clinical Practice Research Datalink, London, UK
Presentation
Andreas Fuchs, Consulting Pharmacist, AOK PLUS, Dresden, Germany

 

W17 : CHALLENGES AND SOLUTIONS TO SUCCESSFULLY DETERMINE REAL-WORLD COST-EFFECTIVENESS

Presentation
Hedwig M. Blommestein, Researcher, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam; Comprehensive Cancer Organisation, Utrecht; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Saskia de Groot, Researcher, Institute of Health Policy & Management, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Margreet G. Franken, Researcher, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Annet F.M. van Abeelen, Pharmaco Economics & Access Manager, Health Economics and Business Development, Roche Pharmaceuticals Netherlands, Woerden, The Netherlands

 

W18 : UTILITIES IN HTA: CHALLENGES FOR THEORY AND PRACTICE NOW AND IN THE FUTURE

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Nancy Devlin, Director of Research, Office of Health Economics, London, UK
Jenny Berg, Senior Scientist, Mapi, Stockholm, Sweden

 

W19 : ESTIMATION AND PREDICTION OF RELATIVE EFFECTIVENESS USING REAL-WORLD EVIDENCE: CASE STUDIES

Presentation
Keith R Abrams, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK
Presentation
Sandro Gsteiger, HTA Statistician, MORSE - Health Technology Assessment Group, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Presentation
Eva-Maria Didden, Researcher, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

 

W20 : HOW TO BRING PRO DATA INTO PAYER DECISION MAKING: PRO STRATEGIES IN PHARMACEUTICAL DEVELOPMENT

Presentation
Vasudha Bal, Director, Patient Reported Outcomes, Worldwide Health Outcomes, Value & Access, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Presentation
Frank-Ulrich Fricke, Professor of Health Economics, Georg-Simon-Ohm University of Applied Science, Nurnberg, Neumarkt, Germany
Presentation
Lynda Doward, European Head, Patient Reported Outcomes, RTI Health Solutions, Manchester, UK

 

W21 : OPTIMISING THE CONSTRUCTION OF INDIRECT TREATMENT COMPARISONS TO REFLECT COUNTRY-SPECIFIC HTA REQUIREMENTS

Presentation
Marc Bardou, Gastroenterologist, Centre Hospitalier Universitaire Le Bocage, Dijon, France
Mathias Flume, Head of Department, Medical Association of Westphalia-Lippe (KVWL), Dortmund, Germany
Rachel Beckerman, Principal, Maple Health Group, New York, NY, USA
Christine G. Kohn, Assistant Professor, School of Pharmacy, University of Saint Joseph/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA

 

W22 : HARNESSING “BIG DATA” AND TAMING HIGH DIMENSIONAL DECISION PROBLEMS FOR ECONOMIC EVALUATION

Presentation
William H. Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Presentation
Miqdad Asaria, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Sarah Davis, Senior Lecturer in Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

 

W23 : ADDING VALUE TO EQ-5D-3L VALUATION STUDIES: TAKING STOCK / REVIEWING OPTIONS

Presentation
Roisin Adams, Deputy Head, National Centre for Pharmacoeconomics, Dublin, Ireland
Paul Kind, Professor, Centre for Health Economics, Management and Policy, HSE University, St Petersburg, Russia
Luciana Scalone, Head of Outcomes Research Unit, Research Centre on Public Health (CESP), University of Milan Bicocca, Monza, Italy
Ling-Hsiang Chuang, Research Consultant, Pharmerit Europe, Rotterdam, The Netherlands

 

W24 : ARE ANTIMICROBIALS PAVING THE WAY FOR ALL PHARMACEUTICALS? – A WORKSHOP ON THE COMMERCIAL SUSTAINABILITY OF R&D

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Monique Martin, Vice President & General Manager HEOR Europe, MAPI, Uxbridge, UK
Alistair Mcguire, Professor of Health Economics, LSE Health, London School of Economics, London, UK

 

W26 : MAXIMIZING VALUE: REALIZING THE POTENTIAL OF ROUTINELY COLLECTED DATA

Presentation
Heiner C. Bucher, Professor, Department of Clinical Research, Basel Institute for Clinical Epidemiology & Biostatistics, Basel, Switzerland
Presentation
Ed Mills, Director, Redwood Outcomes, Vancouver, BC, Canada

 

W27 : ASSESSING THE SOCIETAL, HEALTH CARE, AND PATIENT IMPACT OF LARGE HEALTHCARE INNOVATION PARTNERSHIPS USING HEALTH ECONOMIC MODELING METHODS: LESSONS FROM THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING (EIP ON AHA)

Presentation
Leandro Pecchia, Assistant Professor, School of Engineering, University of Warwick, Coventry, UK

 

W28 : SECONDARY ANALYSIS OF QUALITATIVE DATA TO INFORM THE DEVELOPMENT OF PRO INSTRUMENTS

Presentation
Monica Hadi, Research Manager, Patient-Centered Outcomes, Mapi Group, London, UK
Paul Swinburn, Research Director, Patient-Centered Outcomes, Mapi Group, London, UK
Elizabeth Gibbons, Senior Research Scientist, Health Services Research Unit, University of Oxford, Oxford, UK

 

W29 : HOW SHOULD WE BE RESPONDING TO CONDITIONAL APPROVALS FROM HTA BODIES?

Presentation
Alan A Martin, Director, Value Evidence Analytics, Research and Development, GlaxoSmithKline, Uxbridge, UK
Presentation
Yumi Asukai, Director Value Evidence Analytics, Research and Development, GlaxoSmithKline, Uxbridge, UK
Presentation
Mondher Toumi, Professor of Public Health, Department of Public Health, Aix-Marseille University, Marseilles, France

 

W30 : MANAGING THE EFFECTS OF CHANNELING IN RELATIVE EFFECTIVENESS STUDIES OF NEWLY LAUNCHED MEDICATIONS

Presentation
Billy Amzal, Global Scientific Vice President, LASER Analytica, London, UK
Presentation
Christiane Gasse, Senior Researcher, Aarhus Universitet, Aarhus, Denmark

 

W31 : NETWORK META ANALYSIS MODELS FOR DOSE-RESPONSE AND CLASS EFFECTS IN DECISION MAKING

Presentation
Rhiannon Kate Owen, Research Associate/NIHR Doctoral Research Fellow, Department of Health Sciences, University of Leicester, Leicester, UK
Presentation
Timothy Reason, Senior Consultant, Real-World Evidence Solutions, IMS Health, London, UK
Presentation
David Mawdsley, Research Associate, School of Social and Community Medicine, University of Bristol, Bristol, UK

 

W32 : HOW TO COMBINE OPEN ACCESS ARTICLES AND OPEN ACCESS ECONOMIC EVALUATION MODELS IN HEALTH CARE PROGRAMMES: REAL TIME UPDATING AND LOCAL CUSTOMIZATION OF PUBLISHED ECONOMIC MODELS

Presentation
Giorgio L. Colombo, Professor Department of Drug Sciences, School of Pharmacy, University of Pavia, Milan, Italy
Sandra Le, Editorial Development Manager, Dove Medical Press Limited, Macclesfield, UK
Stefano Govoni, Pharmacologist & Professor Department of Drug Sciences, School of Pharmacy, University of Pavia, Milan, Italy
Laura Caresia, Physician & Medical Director, McCann Complete Medical, Milan, Italy

 

W33 : UNCERTAINTY OF UNCERTAINTY ESTIMATES IN ECONOMIC MODELLING OF ONCOLOGY

Presentation
Noemi Muszbek, Senior Research Scientist, Evidera, London, UK
Presentation
Zoltán Kaló, Professor of Health Economics, Department of Health Policy and Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary

 

ISPOR FORUMS

F1 : RARE DISEASE CLINICAL TRIALS – EMERGING GOOD PRACTICES FOR CLINICAL OUTCOMES ASSESSMENT OUTCOMES (PROS, CLINROS, OSBROS)

Presentation
Katy Benjamin, Director, Patient Reported Outcomes, ICON, Bethesda, MD, USA
Margaret K Vernon, Senior Research Scientist, Evidera, London, UK
Donald Patrick, Professor, Department of Health Services & Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA
Eleanor M. Perfetto, Professor, Pharmaceutical Health Services Research, University of Maryland, and Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA

 

F2 : MAPPING TO ESTIMATE UTILITY VALUES FOR COST PER QALY ECONOMIC ANALYSIS - GOOD RESEARCH PRACTICES

Presentation
Andrea Manca, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Allan J Wailoo, Professor of Health Economics, ScHARR, University of Sheffield and Director, NICE Decision Support Unit, Sheffield, UK
Jan van Busschbach, Professor, Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Joshua Ray, Head of Health Economics Modelling, F. Hoffman-La Roche, Basel, Switzerland

 

F3 : MEDICAL NUTRITION – TERMS, DEFINITIONS, REGULATIONS & EMERGING GOOD PRACTICES FOR ECONOMIC EVALUATION

Presentation
Josephine A. Mauskopf, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Karen Freyer, Nutritionist & Nutrition Economist, School for Public Health and Primary Care (CAPHRI), Maastricht University, Zoetermeer, The Netherlands
Sheri Volger, Principal Clinical Scientist, Nestle Nutrition R&D, King of Prussia, PA, USA
Oznur Sehun, Senior Market Access Manager, Abbott Nutrition, Istanbul, Turkey

 

F4 : HEALTH TECHNOLOGIES PRICING AND DECISION MAKING IN THE CENTRAL SOUTH EUROPE: WHAT, WHERE, WHEN, AND HOW?

Presentation
Mary Geitona, Professor, University of Peloponnese, Athens, Greece
Presentation
Pero Draganic, Assistant Professor, Principal Advisor for Safe Use of Medicines, HALMED, Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia
Presentation
Tomas Dolezal, Director, iHETA, Prague, Czech Republic
Presentation
Bertalan Nemeth, Senior Health Economist, Syreon Research Institute, Budapest, Hungary
Presentation
Malwina Holownia, Director of Economics, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

 

F5 : PARALLEL TRADE: CAN WE CURB THE IMPACT ON CENTRAL & EASTERN EUROPE (CEE) COUNTRIES?

Presentation
Zoran Sterjev, Assistant Professor, Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia
Presentation
Jana Skoupa, Researcher, Charles University, Prague, Czech Republic
Presentation
Assena Stoimenova, Associate Professor and Executive Director, The Bulgarian Drug Agency, Sofia, Bulgaria
Presentation
Nataša Bogavac-Stanojevic, Assistant Professor, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

 

F6 : BUDGET RESTRICTIONS FOLLOWING THE ECONOMIC CRISIS: THREATS OR OPPORTUNITIES FOR THE DEVELOPMENT OF ECONOMIC EVALUATION IN THE SOUTHERN EUROPEAN REGION

Presentation
Carlos Gouveia Pinto, President, ISPOR Portugal Chapter, Associate Professor, Institute for Advanced Studies in Economics and Management & President, Research Center on the Portuguese Economy (CISEP), School of Economics & Management, University of Lisbon, Lisbon, Portugal
Presentation
Carme Pinyol, Founder & Director, INNOVA -Strategic Consulting, Barcelona, Spain
Presentation
Americo Cicchetti, Professor of Management and Healthcare Management & Director, Graduate School of Health Economics and Management, Catholic University of Sacred Heart (ALTEMS), Rome, Italy

 

F7 : CONJOINT ANALYSIS: GOOD RESEARCH PRACTICES FOR STATISTICAL ANALYSIS

Presentation
A. Brett Hauber, Senior Economist & Global Head, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
Karin G. M. Groothuis-Oudshoorn, Assistant Professor, Health Technology and Services Research, University of Twente, Enschede, The Netherlands
Maarten Ijzerman, Assistant Professor, Health Technology and Services Research, University of Twente, Enschede, The Netherlands

 

F8 : PATIENT ENGAGEMENT: WHAT IS IN A NAME?

Presentation
Eleanor M Perfetto, Professor, Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, and Senior Vice President, Strategic Initiatives, National Health Council, Washington, MD, USA
Russell Wheeler, Patient Advocate, Leber's Hereditary Optic Neuropathy, Winchester, UK
Donald L. Patrick, Director, Seattle Quality of Life Group and Biobehavioral Cancer Prevention and Training Program, University of Washington, Seattle, WA, USA

 

F9 : MULTI-CRITERIA DECISION MAKING IN THE CENTRAL & EASTERN EUROPEAN (CEE) REGION: ARE WE THERE YET?

Presentation
Rok Hren, President, ISPOR Slovenia Chapter and Assistant Professor, University of Ljubljana, Ljubljana, Slovenia
Presentation
Oresta Piniazhko, PhD student, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
Maciej Niewada, CEO, HealthQuest and Professor, Department of Clinical & Experimental Pharmacology of Medical University of Warsaw, Warsaw, Poland
Presentation
Zoltan Kalo, Professor of Health Economics, Department of Health Policy and Economics, Faculty of Social Sciences, Eötvös Loránd University, Budapest, Hungary

 

F10 : MARKET ACCESS PRICING IN CENTRAL & EASTERN EUROPE (CEE): PRACTICAL GUIDE TO SUCCESSFUL REIMBURSEMENT

Presentation
Olha Zaliska, President, ISPOR Ukraine Chapter and Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
Tarik Catic, Researcher and President, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
Presentation
Yalcin Kaya, Public Health Specialist, Senior Manager, Market Access, Public Affairs and Corporate Affairs, Bristol-Myers Squibb, Istanbul, Turkey

 

EDUCATIONAL SYMPOSIA

CHALLENGES AND OPPORTUNITIES IN HEART FAILURE: UNMET CLINICAL NEEDS, ECONOMIC BURDEN, AND IMPACT ON SOCIETY

Presentation
Lorenzo G. Mantovani, Doctor, Center for Public Health Research, Università degli Studi di Milano - Bicocca, Monza, Italy
Presentation
Joe Gallagher, Doctor, University College Dublin, Dublin, Ireland
Presentation
Lorenzo G. Mantovani, Doctor, Center for Public Health Research, Università degli Studi di Milano - Bicocca, Monza, Italy
Presentation
Javier Mar Medina, Doctor, Hospital Alto Deba, Mondragón, Spain
Presentation
Joe Gallagher, Doctor, University College Dublin, Dublin, Ireland

 

NEW APPROACHES TO CAPTURING VALUE IN ONCOLOGY

Presentation
Wolfgang Greiner, Professor of Health Economics and Health Management, Bielefield University, Bielefeld, Germany
David Chao, Consultant in Medical Oncology, Royal Free Hospital, London, UK
Isabelle Durand-Zaleski, Professor of Public Health, URCEco Ile de France Hôpital de l'Hotel Dieu, Paris, France
Scott Ramsey, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 18th Annual European Congress, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 18th Annual European Congress – Milan, Italy
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS

ISPOR Rare Disease

EDUCATIONAL FORUM

ISPOR Educational Forum: Resilient Off-Patent Drug Policies for Emerging Markets

STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.